Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 3/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRND | Q07001 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 5/20 | 0.40 |
| ▸ | TDO2 | P48775 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148071 | 0.88 | CHRNB4 (0.43) | PRKCICHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14409567 | 0.83 | PRKCI (0.51) | PRKCIAKT1CHRNB4CHRNA3IDO1 | |
| SCHEMBL14416942 | 0.83 | PRKCI (0.51) | PRKCIAKT1CHRNB4CHRNA3IDO1 | |
| SCHEMBL14416943 | 0.83 | PRKCI (0.51) | PRKCIAKT1CHRNB4CHRNA3IDO1 | |
| SCHEMBL4924400 | 0.80 | ROCK2 (0.48) | — | |
| SCHEMBL4930989 | 0.79 | MKNK1 (0.44) | MAPTGSK3B | |
| SCHEMBL4925453 | 0.79 | ROCK2 (0.45) | MAPTGSK3B | |
| SCHEMBL4148646 | 0.79 | KDM4C (0.45) | MAPTGSK3B | |
| SCHEMBL4159891 | 0.78 | SYK (0.46) | CHRNB2CHRNA4GSK3B | |
| SCHEMBL14603115 | 0.77 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | BIOFOCUS DISCOVERY LTD. | 2009-06-25 | — | — | US | disclosed |
| WO-2006072792-A2 | COMPOUNDS WHICH BIND TO THE ACTIVE SITE OF PROTEIN KINASE ENZYMES | GALAPAGOS NV (BE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163515-A1 | Compounds Which Bind to the Active Site of Protein Kinase Enzymes | ROCK1, ROCK2, CIT | PRKCI 106/4885AKT1 83/4885CHRNB2 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.